OS1.2 Stability of EGFR amplification in glioblastoma is differentially impacted based on therapeutic pressure

BACKGROUND: Depatuxizumab mafodotin (depatux-m, formerly ABT-414) is an EGFR-directed antibody-drug conjugate being developed for treatment of EGFR-amplified glioblastoma (GBM). As therapeutic pressure engenders tumor adaptations, it is important to understand the stability of biomarkers targeted by...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Ahluwalia, M, Narita, Y, Muragaki, Y, Gan, H, Merrell, R, van den Bent, M, Roberts-Rapp, L, Guseva, M, Ansell, P, Lassman, A
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2018
Konular:
Oral Presentations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144113/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.008
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller